NDA 208026 · Boehringer Ingelheim
Jentadueto Xr
Linagliptin, Metformin Hydrochloride · Oral · Dipeptidyl Peptidase 4 Inhibitor
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
May 27, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
195
53 Phase 3, 5 recruiting
FAERS reports
67
26 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...
What it is approved for
From the label in effect Aug 19, 2026.
JENTADUETO XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitations of Use JENTADUETO XR is not recommended in patients with type 1 diabetes mellitus. JENTADUETO XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using JENTADUETO XR [see Warnings and Precautions (5.2) ]. JENTADUETO XR is a combination of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ) Limitations of Use Not recommended in patients with type 1 diabetes mellitus ( 1 ) Has not been studied in patients with a history of pancreatitis ( 1 )
Mechanism: JENTADUETO XR JENTADUETO XR contains: linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Linagliptin Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 2023 Supplement 24 · Efficacy · priority review LetterLabel
- Mar 30, 2020 Supplement 12 · Efficacy LetterLabel
- Jul 3, 2019 Supplement 8 · Efficacy LetterLabel
- May 27, 2016 Original approval · Type 4 - New Combination LabelReviewSummary Review
2 products under this application
- JENTADUETO XR · LINAGLIPTIN 5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
- JENTADUETO XR · LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Linagliptin" as an intervention, any sponsor and status, largest first.
- Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01897532 · 6,991 participants · Start Jul 10, 2013 · Primary completion Jan 18, 2018
Drug: Placebo; Linagliptin · For: Diabetes Mellitus, Type 2
Sites: Huntsville, Alabama; Scottsboro, Alabama; Tuscumbia, Alabama · 649 sites in all
- CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01243424 · 6,103 participants · Start Nov 11, 2010 · Primary completion Aug 21, 2018
Drug: linagliptin; glimepiride and 2 more · For: Diabetes Mellitus, Type 2
Sites: Athens, Alabama; Birmingham, Alabama; Mobile, Alabama · 613 sites in all
- Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DMPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00736099 · 2,122 participants · Start Aug 2008 · Primary completion Dec 2010
Drug: linagliptine 5 mg; linagliptine 5 mg and pioglitazone 30 mg · For: Diabetes Mellitus, Type 2
Sites: Chula Vista, California; Spring Valley, California; Walnut Creek, California · 232 sites in all
- Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00622284 · 1,560 participants · Start Feb 2008 · Primary completion Dec 2010
Drug: Placebo identical to BI 1356 5mg; Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg and 2 more · For: Diabetes Mellitus, Type 2
Sites: Tempe, Arizona; Chula Vista, California; Los Angeles, California · 221 sites in all
- Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01422876 · 1,405 participants · Start Aug 2011 · Primary completion Sep 2013
Drug: high dose FDC; BI 10773 high dose and 23 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Foley, Alabama; Mobile, Alabama · 211 sites in all
- Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00954447 · 1,263 participants · Start Aug 2009 · Primary completion Sep 2011
Drug: Placebo; Linagliptin · For: Diabetes Mellitus, Type 2
Sites: Escondido, California; Fresno, California; Greenbrae, California · 169 sites in all
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialPivotal-lookingStatus unknown
Center for Outcomes Research and Clinical Epidemiology, ItalyAcademic, hospital or other
NCT04796428 · 1,167 participants (planned) · Start Jun 30, 2021 · Primary completion Dec 31, 2023
Drug: Canagliflozin; Dapagliflozin and 1 more · For: Diabetes Mellitus, Type 2
- BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00602472 · 1,058 participants · Start Feb 2008 · Primary completion May 2009
Drug: linagliptin; placebo · For: Diabetes Mellitus, Type 2
Sites: Capital Federal, Argentina; Corrientes, Argentina; Córdoba, Argentina · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased7
- weight decreased6
- diarrhoea5
- malaise4
- pancreatitis4
- tremor3
- abdominal pain upper2
- asthenia2
- blood glucose abnormal2
- confusional state2
- death2
- decreased appetite2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 3 |
| 2018 | 12 |
| 2019 | 5 |
| 2020 | 16 |
| 2021 | 4 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 5 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jentadueto XR (Linagliptin/Metformin HCl)
2024 spending
$31.0M
Beneficiaries
7,975
38,263 claims
Per beneficiary
$3,883
$12.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,731,410 |
| 2021 | $26,600,679 |
| 2022 | $28,806,030 |
| 2023 | $29,897,203 |
| 2024 | $30,970,140 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
DeFronzo RA, Lewin A, Patel S, et al. · Diabetes Care 2015 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Multicenter Study
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J, Perkovic V, Johansen OE, et al. · JAMA 2019 · Comparative Study, Equivalence Trial
- Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Chenchula S, Varthya SB, Padmavathi R · Curr Diabetes Rev 2022 · Systematic Review
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, et al. · Front Endocrinol (Lausanne) 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P · Clin Ther 2014 · Systematic Review
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.